Untitled

Aberdein, Jody; Singer, Mervyn

doi:10.1186/cc3904

Cited by 24 publications

(15 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, neuroinflammatory diseases such as meningitis are treated with corticosteroids in combination with antibacterial, antiviral, or antifungal agents (Aberdein and Singer, 2006; Hoffman and Weber, 2009). Corticosteroids have both anti-inflammatory and immunosuppressive properties and treatment with these agents has been shown to reduce the risk of hearing loss and mortality due to meningitis.…”

Section: Discussionmentioning

confidence: 99%

The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders

Johnson

Young

Marriott

2017

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The inflammatory responses of resident central nervous system (CNS) cells are now known to play a critical role in the initiation and progression of an array of infectious and sterile neuroinflammatory disorders such as meningitis, encephalitis, Parkinson’s disease, Alzheimer’s disease and multiple sclerosis (MS). Regulating glial inflammatory responses in a timely manner is therefore critical in preserving normal CNS functions. The neuropeptide substance P is produced at high levels within the CNS and its selective receptor, the neurokinin 1 receptor (NK-1R), is abundantly expressed by neurons and is present on glial cell types including microglia and astrocytes. In addition to its functions as a neurotransmitter in the perception of pain and its essential role in gut motility, this tachykinin is widely recognized to exacerbate inflammation at peripheral sites including the skin, gastrointestinal tract and the lungs. Recently, a number of studies have identified a role for substance P and NK-1R interactions in neuroinflammation and described the ability of this neuropeptide to alter the immune functions of activated microglia and astrocytes. In this review article, we describe the expression of substance P and its receptor by resident CNS cells, and we discuss the ability of this neuropeptide to exacerbate the inflammatory responses of glia and immune cells that are recruited to the brain during neurodegenerative diseases. In addition, we discuss the available data indicating that the NK-1R-mediated augmentation of such responses appears to be detrimental during microbial infection and some sterile neurodegenerative disorders, and propose the repurposed use of NK-1R antagonists, of a type that are currently approved as anti-emetic and anti-anxiolytic agents, as an adjunct therapy to ameliorate the inflammatory CNS damage in these conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders

Johnson

Young

Marriott

2017

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Corticosteroids have been used for more than 60 years as adjunctive treatments of infections to mitigate local and systemic inflammatory responses. ( 20 ) These drugs are commonly used among critically ill patients, and a significant number of studies have demonstrated the benefits of using corticosteroids for patients in septic shock because they are associated with initial shock reversal, the mitigation of systemic inflammatory response indicators, and significant decreases in mortality. ( 21 , 22 )…”

Section: Discussionmentioning

confidence: 99%

Drug incompatibilities in the adult intensive care unit of a university hospital

Marsilio¹,

Silva²,

Bueno³

2016

Revista Brasileira De Terapia Intensiva

View full text Add to dashboard Cite

ObjectivesThis study sought to identify the physical and chemical incompatibilities among the drugs administered intravenously to patients admitted to an adult intensive care unit. We also aimed to establish pharmaceutical guidelines for administering incompatible drugs.MethodsThis cross-sectional, prospective, and quantitative study was conducted from July to September 2015. Drug incompatibilities were identified based on an analysis of the patient prescriptions available in the hospital online management system. A pharmaceutical intervention was performed using the guidelines on the preparation and administration of incompatible drugs. Adherence to those guidelines was subsequently assessed among the nursing staff.ResultsA total of 100 prescriptions were analyzed; 68 were incompatible with the intravenous drugs prescribed. A total of 271 drug incompatibilities were found, averaging 4.0 ± 3.3 incompatibilities per prescription. The most commonly found drug incompatibilities were between midazolam and hydrocortisone (8.9%), between cefepime and midazolam (5.2%), and between hydrocortisone and vancomycin (5.2%). The drugs most commonly involved in incompatibilities were midazolam, hydrocortisone, and vancomycin. The most common incompatibilities occurred when a drug was administered via continuous infusion and another was administered intermittently (50%). Of the 68 prescriptions that led to pharmaceutical guidelines, 45 (66.2%) were fully adhered to by the nursing staff.ConclusionPatients under intensive care were subjected to a high rate of incompatibilities. Drug incompatibilities can be identified and eliminated by the pharmacist on the multidisciplinary team, thereby reducing undesirable effects among patients.

show abstract

“…[1][2][3] Although long-term corticosteroid use with its attendant immunosuppression could increase the risk for abscess formation, a short course is unlikely to have the same effect. [4][5][6] The diagnosis of iliopsoas abscess can be difficult to make, and delays in diagnosis can result in sepsis and organ failure and are known to increase mortality. 2,3,7 Hip pain with impaired flexion and antalgic gait are characteristic complaints associated with iliopsoas abscesses and can serve as diagnostic clues.…”

Section: Discussionmentioning

confidence: 99%